Home	Quick Product Lists	Contact LC Labs	Login/Register	My Account	View Cart
In Business 32 Years - Since 1980		THE CURRENT TIME at LC Labs is:
		Search:  Product Pages Only  Entire Site

C-1502 Celecoxib, >99%

[Celebrex] [Celebra] [Celecox] [Onsenal] [Solexa] [SC-58635] [YM-177]

M.W. 381.37

C17H14F3N3O2S

[169590-42-5]

M.I. 14:  1956

Storage:  Store at or below -20 ºC.  Solubility:  Soluble in DMSO at 200 mg/mL; soluble in ethanol at 100 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-50 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility.  Disposal:  A

Find and View a Certificate of Analysis for this product

View the MSDS for this product

• Celecoxib is a highly selective COX-2 inhibitor and primarily inhibits prostaglandin production.

• Celecoxib is approximately 7.6-fold more selective for COX-2 inhibition over COX-1.  This specificity allows celecoxib to reduce inflammation and pain while minimizing gastrointestinal adverse drug reactions (e.g. stomach ulcers) that are common with non-selective non-steroidal anti-inflammatory drugs (NSAIDs).  Silverstein, F.E., et al.  "Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study."  JAMA. 284:  1247-1255 (2000).

• Celecoxib and other COX-2 inhibitors increase the risk of myocardial infarction.  Caldwell, B., et al.  "Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis."  J. R. Soc. Med. 99:  132-140 (2006).

• COX-2 not only plays an important role in inflammation but also is involved in multiple biologic events throughout the tumorigenic process.  COX-2 inhibitors may act additively or synergistically with currently used cytotoxics and molecularly targeted agents to prevent and treat cancers.  Koki, A.T. and Masferrer, J.L.  "Celecoxib: a specific COX-2 inhibitor with anticancer properties."  Cancer Control. 9:  28-35 (2002).

• Celecoxib shows competitive kinetics on COX-1 (Ki = 10-16 µM).  It also displays an initial competitive interaction with COX-2 (Ki = 11-15 µM), followed by a time-dependent interaction leading to potent inhibition and inactivation (Kinact = 0.03-0.5 s-1).  Half-maximal inhibition (IC50) using end-point assays demonstrates the competitive component on COX-1 (IC50 = 4-19 µM) and the inactivation component on COX-2 (IC50 = 0.003-0.006 µM).  Gierse, J.K., et al.  "Kinetic basis for selective inhibition of cyclo-oxygenases."  Biochem J. 339:  607-614 (1999).

• Celecoxib is the active ingredient in the drug sold under the trade name Celebrex® or Celebra® in some countries.  It has been approved in at least one country for treatment of patients with osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and it is also used to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis.  NOTE:  The celecoxib sold by LC Laboratories is NOT Celebrex® or Celebra®, and is NOT for human use.

• Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.

• This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.

• Not available in some countries; not available to some institutions; not available for some uses.